Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
105.76M | 113.45M | 794.00K | 7.34M | 20.95M | Gross Profit |
101.87M | 108.81M | -4.00K | -42.00K | 11.79M | EBIT |
16.16M | -67.23M | -8.61M | -87.89M | -57.37M | EBITDA |
16.16M | 20.33M | 10.33M | -87.60M | -57.37M | Net Income Common Stockholders |
12.09M | -92.93M | 2.30M | -87.93M | -55.54M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
11.81M | 33.51M | 21.67M | 46.85M | 79.35M | Total Assets |
125.41M | 116.54M | 28.44M | 55.66M | 94.85M | Total Debt |
1.60M | 409.00K | 38.00K | 2.38M | 1.64M | Net Debt |
-10.21M | -33.10M | -21.63M | -41.96M | -28.72M | Total Liabilities |
27.00M | 38.06M | 50.13M | 14.57M | 18.78M | Stockholders Equity |
63.32M | -15.83M | -21.69M | 41.09M | 76.07M |
Cash Flow | Free Cash Flow | |||
-5.96M | 17.31M | -38.09M | -84.59M | -55.31M | Operating Cash Flow |
-3.64M | 25.89M | -33.10M | -83.75M | -55.05M | Investing Cash Flow |
-19.88M | -19.76M | 55.43M | 48.19M | 9.66M | Financing Cash Flow |
2.10M | 2.50M | -45.01M | 49.55M | 60.38M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
52 Neutral | $689.65M | ― | 222.83% | ― | 23.89% | 16.86% | |
52 Neutral | $5.28B | 3.75 | -42.72% | 2.86% | 17.70% | 2.03% | |
49 Neutral | $741.99M | ― | -14.75% | ― | -24.17% | -9.24% | |
47 Neutral | $875.56M | 79.83 | -57.18% | ― | ― | ― | |
47 Neutral | $850.79M | ― | -64.16% | ― | -30.25% | -5.92% | |
42 Neutral | $1.00B | ― | -41.43% | ― | ― | 0.71% | |
39 Underperform | $894.39M | ― | -54.00% | ― | 59.55% | 3.09% |
On April 28, 2025, Gyre Therapeutics released an updated corporate presentation highlighting its pioneering efforts in fibrosis treatment. The presentation detailed the company’s robust pipeline, including its lead asset F351, which targets chronic hepatitis B-related liver fibrosis, a significant unmet medical need in China. Gyre’s strategic approach involves a China-first validation strategy to leverage faster patient enrollment and cost efficiency, followed by expansion into the U.S. This strategy aims to mitigate clinical and regulatory risks while maintaining market leadership since the commercialization of pirfenidone in 2014.
Spark’s Take on GYRE Stock
According to Spark, TipRanks’ AI Analyst, GYRE is a Neutral.
Gyre Therapeutics faces significant challenges, particularly in financial stability and valuation. The company’s operational efficiencies show improvement, yet revenue volatility and cash flow issues raise concerns. Technical indicators reflect mixed signals, with potential bearish momentum. The high P/E ratio indicates overvaluation, and the lack of a dividend yield may deter some investors. These elements collectively result in a modest stock score.
To see Spark’s full report on GYRE stock, click here.
GNI Group Ltd., which has an indirect controlling interest in Gyre Therapeutics, Inc., reported its financial results for the fiscal year ending December 31, 2024. The company, involved in pharmaceuticals and clinical trials, experienced a decline in revenue and profits compared to 2023. Despite this, GNI anticipates significant developments in 2025, including Phase 3 trial results for Hydronidone in China and other clinical advancements. These upcoming milestones could potentially enhance GNI’s position in the pharmaceuticals market, particularly in liver disease treatment.